UW (perfusion solution) + sodium thiosulfate (STS) for Kidney Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kidney Diseases+2 More
Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will determine if thiosulfate improves kidney function in recipients of deceased donor kidneys.

Eligible Conditions
  • Kidney Diseases
  • End Stage Renal Disease (ESRD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Kidney Diseases

Study Objectives

5 Primary · 3 Secondary · Reporting Duration: 1 year

1 week
Biopsy proven Acute tubular necrosis (ATN)
Patient urine output
Urinary injury biomarkers (KIM-1/NGAL).
Urine protein/creatinine ratio
1 week after transplant
Serum Creatinine
Slow Graft Function
eGFR
1 year
Change in Patient urine output

Trial Safety

Safety Progress

1 of 3

Other trials for Kidney Diseases

Trial Design

2 Treatment Groups

UW (perfusion solution) + sodium thiosulfate (STS)
1 of 2
UW (perfusion solution)
1 of 2
Active Control

100 Total Participants · 2 Treatment Groups

Primary Treatment: UW (perfusion solution) + sodium thiosulfate (STS) · No Placebo Group · Phase 1

UW (perfusion solution) + sodium thiosulfate (STS)
Drug
ActiveComparator Group · 1 Intervention: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% · Intervention Types: Drug
UW (perfusion solution)NoIntervention Group · 1 Intervention: UW (perfusion solution) · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
613 Previous Clinical Trials
399,985 Total Patients Enrolled
18 Trials studying Kidney Diseases
28,390 Patients Enrolled for Kidney Diseases
Alp Sener, Dr.Principal InvestigatorLHSC

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.